Nuveen Asset Management, LLC Outlook Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.02 - $1.89 $261,827 - $485,151	-256,694 Reduced 30.0%	598,961 $1.04 Million
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $49,271 - $66,515	49,271 Added 6.11%	855,655 $932,000
Q4 2022 Feb 14, 2023	SELL	$0.87 - $1.33 $25,126 - $38,411	-28,881 Reduced 3.46%	806,384 $871,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $8,518 - $10,522	8,351 Added 1.01%	835,265 $1.02 Million
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $107,293 - $236,989	-117,905 Reduced 12.48%	826,914 $843,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $870,671 - $1.45 Million	713,665 Added 308.74%	944,819 $1.92 Million
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $36,267 - $63,682	-28,557 Reduced 11.0%	231,154 $308,000
Q3 2021 Nov 12, 2021	BUY	$2.12 - $2.76 $152,765 - $198,882	72,059 Added 38.4%	259,711 $625,000
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $334,020 - $517,919	187,652 New	187,652 $468,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.